Foundayo, a daily pill, successfully reduced obstructive sleep apnea, according to clinical trial data ...

Lilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea ...

Nov 9 (Reuters) - Eli Lilly said on Monday its oral weight-loss drug Foundayo significantly reduced breathing interruptions ...

If approved, the oral GLP-1 would be Eli Lilly’s second marketed drug for obstructive sleep apnea after the GIP/GLP-1 ...

Eli Lilly reported results from new studies exploring the effects of its GLP-1 weight-loss drugs on sleep apnea and arthritis ...

Sleep apnea does not always announce itself with thunderous snoring. In women, it may present more like insomnia, morning ...

A new study from Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center may have uncovered a ...

Sleep Physician Dr. Yatin J. Patel hopes to change the sleep apnea conversation with his new book, "CPAP Is Sexy: How ...

Eli Lilly could soon see two label expansions for Foundayo, it’s oral GLP-1, in swift succession: In September, the drugmaker ...

Eli Lilly & Co.’s weight loss pill Foundayo helped control sleep apnea in two large trials, reducing nighttime disruptions ...

Sleep.ai raises $5.3M as real-world sleep data hits 1.1B hours, normalizing 800 wearables and scaling Germany's nationally ...